Epstein Barr virus-associated lymphoproliferative diseases: the virus as a therapeutic target.

Exp Mol Med · 2015 · PMC4314579 · PMID 25613733

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

an increasing trendno p-value reported

10 , 11 , 12 Once an increasing trend of circulating EBV DNA is detected, reduction or withdrawal of immunosuppression should be instituted. 8 Because most cases of EBV+ PTLD post HSCT involve CD20+ B cells, the preemptive use of rituximab has been shown to abort the development of clinical disease. 8 , 12 , 13 However, when PTLD has developed, the use of rituximab and chemotherapy is less effective.

also in 63,971 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.